|
|
Long-Chain Fatty Acid Oxidation Disorders: Advances in Nutritional Management
Target Audience
This activity is designed to meet the educational needs of Registered Dietitians.
Program Overview
Long-chain fatty acid oxidation disorders (LC-FAODs) are characterized by acute crises of energy production and chronic energy deficiency during times of physiologic stress and fasting. Clinical complications include recurrent episodes of rhabdomyolysis, weakness, hepatic dysfunction, severe hypoglycemia, hyperammonemia, and cardiomyopathy. Despite a traditional diet therapy,... |
|
|
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided wit... |
|
|
Lp(a) and LDL-C Management: Exploring Divergent Perspectives
Target Audience
The intended audience for this activity is cardiologists, endocrinologists, internists, pharmacists, nurses, and other healthcare professionals involved in the management of patients with hyperlipidemia and other cardiovascular risk factors.
Program Overview
Lp(a) and LDL-C Management: Exploring Divergent Perspectives is a continuing education (CE) initiative aimed at broadening healthcare professionals' understanding of the complex nature of hyperlipidemia management... |
|
|
Mastering Suboptimal Treatment Response in nAMD
In this Master Class case, Dr. David Eichenbaum discusses the management of a 69-year-old White man with neovascular age-related macular degeneration who receives a suboptimal treatment response to initial anti-vascular epithelial growth factor therapy. |
|
|
ASCVD Clinical Research Updates Targeting Residual Inflammation in Patients with ASCVD and CKD
Emerging evidence and scientific advancements are revealing pathophysiologic mechanisms correlated with systemic inflammation and the development of atherosclerotic cardiovascular disease (ASCVD). Patients with chronic kidney disease (CKD) are at high risk for developing ASCVD. Novel anti-inflammatory therapies are showing efficacy at reducing inflammation and development of ASCVD, and are adding to the treatment options beyond the usual lipid-lowering agents. As new clinical evidence and tar... |
|
|
Inherited Retinal Diseases: Navigating the Future of Diagnostics and Emerging Therapies
The differential diagnosis and workup of a suspected inherited retinal disease (IRD) can be challenging, requiring the expertise of the multidisciplinary healthcare team. Guidelines released in 2022 by the American Academy of Ophthalmology provide recommendations and clinical genetic assessments for patients with IRDs. Genetic counseling is essential to help patients understand the genetic test results, their implications for prognosis, family planning, and therapeutic decisions. Genetic testi... |
|
|
Overcoming the Hurdles: Advances in the Management of Hemophilia
In this fast-moving, 1-hour accredited activity, Craig Kessler, MD, and Guy Young, MD, share their thoughts and experience with clotting factor concentrates, recombinant factor, factor VIII mimetics, rebalancing agents, and gene therapies. The safety and efficacy of late-phase investigational products are also discussed as these agents have the potential to address unmet needs and further transform patient care. |
|
|
Extending Dosing Intervals in Retinal Disease: Patient Perspectives and Clinical Insights to Guide Your Practice
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are increasingly prevalent retinal diseases that pose significant challenges in ophthalmic care. While anti-vascular endothelial growth factor (VEGF) therapies have greatly improved visual outcomes for patients with these conditions, real-world data indicate that many patients receive suboptimal treatment and monitoring, resulting in poorer visual outcomes. Newer therapeutic options have been developed to exte... |
|
|
Patient‐Centered GA Care: A Synergistic Approach to Optimize Management
The recent FDA approval of 2 novel therapies for the management of patients with geographic atrophy (GA) secondary to age-related macular degeneration has further reenforced the necessity for early GA diagnosis to limit progression. Advances in imaging technologies now provide tools for better detection and characterization of GA, along with biomarkers to monitor progression over time. Optometrists, as front-line eye healthcare providers, play a critical role in the timely diagnosis, managemen... |
|
|
The Retina Radar With Dr. Arshad Khanani on DR, GA, New Mechanisms, and Noninvasive Treatments
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like under-treatment and patient non-adherence. New and emerging therapies, particularly for conditions like diabetic macular edema (DME), diabetic retinopathy, and geographic atrophy (GA) secondary to... |
|
|
GA and Advances in Imaging and Surgery: State-of-the-Art Management
The continued evolution of diagnostic, therapeutic, and surgical algorithms for the management of patients with retinal diseases offer the potential for enhancing visual, anatomical, and quality-of-life outcomes in these patients. Recognition, understanding, and application of these evidence-based advances are imperative to enhance treatment outcomes and patient satisfaction. During Part 2 of this 2-part educational activity, updates in geographic atrophy will be discussed, along with advances... |
|
|
Navigating pain management, safe opioid prescribing, and opioid use disorder
This program is presented in six thirty minute sessions that can be completed individually.
The sessions are:
Session 1: Pain Taxonomy, pathogenesis, and assessment
Session 2: Developing a patient-centered pain treatment plan
Session 3: Non-opioid analgesics: Evidence and clinical pearls
Session 4: Opioid analgesics: From A to Z
Session 5: Clinical use of opioids: Safe prescribing and appropriate monitoring
Session 6: The exit strategy: When the treatment becomes the ... |
|